Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID119031166M in Healthy Participants
NCT05604287Phase 1Terminated
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lecufexor in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Number of participants with Serious Adverse Events (SAEs) and Adverse Events (AEs). Started Oct 2022; status: terminated.
02
Drugs
Lecufexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05604287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604287.